热门资讯> 正文

Precision Biosciences To Be Issued Us Patent For PBGENE-HBVARCUS Nuclease Utilized In The Company's Lead In Vivo Gene Editing Program, The Us Patent Will Have An Expiration Date In March 2042

2025-09-08 19:10

Strengthens the Company's intellectual property portfolio for lead in vivo program PBGENE-HBV with U.S. patent protection into 2042.
Phase 1 ELIMINATE-B trial progressing through clinical investigation with dosing of Cohort 3 initiated in Third Quarter of 2025

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。